View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEpiphany Technology Acquisition 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 14Epiphany Technology Acquisition Corp.(NasdaqCM:EPHY) dropped from NASDAQ Composite IndexEpiphany Technology Acquisition Corp. has been dropped from NASDAQ Composite Index .Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Co-CEO, CFO & Director Peter Bell is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 24Epiphany Technology Acquisition Corp. Appoints Board of DirectorsEffective September 16, 2022, the board of directors of Epiphany Technology Acquisition Corp. approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Louis Lange and Ronald Eastman as members of the Board to fill the vacancies created by the increase. The Board determined that each Messrs. Stephen Sherwin, Louis Lange and Ronald Eastman is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. Ronald Eastman Since December 2021, Ronald Eastman has served as Vice Chairman of BioPlus Acquisition Corp. Mr. Eastman has over 40 years of experience in building and leading both publicly-traded and private healthcare businesses. Mr. Eastman is currently a Senior Advisor of EW Healthcare Partners (EW), where he previously served for 15 years as Managing Director of multiple funds before transitioning to Senior Advisor in 2021. Mr. Eastman led and served on the Board of Directors of EW’s investments in ProteinSimple Inc. (acquired by Bio-Techne Corporation), Corium Inc. (acquired by Gurnet Point Capital), and Open Monoclonal Technology Inc. (acquired by Ligand Pharmaceuticals Inc.). He also currently serves on the Board of Directors of EW portfolio company Suneva Medical Inc. Mr. Eastman began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer Inc.), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. As CEO of Rinat Neuroscience Corporation with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat Neuroscience was acquired by Pfizer Inc. in 2006. Mr. Eastman has also previously served as a board member of Revance Therapeutics Inc., the Biotechnology Innovation Organization, and as a Trustee of the Buck Institute for Research on Aging. Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.お知らせ • Sep 23Epiphany Technology Acquisition Corp. Appoints Ross Haghighat as Co-Chief Executive OfficerThe board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of Epiphany Technology Acquisition Corp., effective September 16, 2022. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.お知らせ • Jun 05Epiphany Technology Acquisition Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QEpiphany Technology Acquisition Corp. announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice (May 28, 2021), or until July 27, 2021, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q (May 24, 2021), or until November 22, 2021, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. As noted above, the Company is working diligently to complete its Form 10-Q. The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rules. No assurance can be given that the Company will be able to regain compliance with the aforementioned listing requirement or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.お知らせ • May 18Epiphany Technology Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Epiphany Technology Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Epiphany Technology Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:EPHY - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2022N/A12-1-1N/A6/30/2022N/A13-1-1N/A3/31/2022N/A6-1-1N/A12/31/2021N/A7-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: EPHYの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: EPHYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: EPHYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: EPHYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: EPHYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EPHYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/15 21:44終値2023/01/12 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Epiphany Technology Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 14Epiphany Technology Acquisition Corp.(NasdaqCM:EPHY) dropped from NASDAQ Composite IndexEpiphany Technology Acquisition Corp. has been dropped from NASDAQ Composite Index .
Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Co-CEO, CFO & Director Peter Bell is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 24Epiphany Technology Acquisition Corp. Appoints Board of DirectorsEffective September 16, 2022, the board of directors of Epiphany Technology Acquisition Corp. approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Louis Lange and Ronald Eastman as members of the Board to fill the vacancies created by the increase. The Board determined that each Messrs. Stephen Sherwin, Louis Lange and Ronald Eastman is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. Ronald Eastman Since December 2021, Ronald Eastman has served as Vice Chairman of BioPlus Acquisition Corp. Mr. Eastman has over 40 years of experience in building and leading both publicly-traded and private healthcare businesses. Mr. Eastman is currently a Senior Advisor of EW Healthcare Partners (EW), where he previously served for 15 years as Managing Director of multiple funds before transitioning to Senior Advisor in 2021. Mr. Eastman led and served on the Board of Directors of EW’s investments in ProteinSimple Inc. (acquired by Bio-Techne Corporation), Corium Inc. (acquired by Gurnet Point Capital), and Open Monoclonal Technology Inc. (acquired by Ligand Pharmaceuticals Inc.). He also currently serves on the Board of Directors of EW portfolio company Suneva Medical Inc. Mr. Eastman began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer Inc.), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. As CEO of Rinat Neuroscience Corporation with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat Neuroscience was acquired by Pfizer Inc. in 2006. Mr. Eastman has also previously served as a board member of Revance Therapeutics Inc., the Biotechnology Innovation Organization, and as a Trustee of the Buck Institute for Research on Aging. Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.
お知らせ • Sep 23Epiphany Technology Acquisition Corp. Appoints Ross Haghighat as Co-Chief Executive OfficerThe board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of Epiphany Technology Acquisition Corp., effective September 16, 2022. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.
お知らせ • Jun 05Epiphany Technology Acquisition Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QEpiphany Technology Acquisition Corp. announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice (May 28, 2021), or until July 27, 2021, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q (May 24, 2021), or until November 22, 2021, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. As noted above, the Company is working diligently to complete its Form 10-Q. The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rules. No assurance can be given that the Company will be able to regain compliance with the aforementioned listing requirement or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.
お知らせ • May 18Epiphany Technology Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Epiphany Technology Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.